A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

NCT07309055 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Adolescents With Moderate-to-severe Atopic Dermatitis

Interventions

DRUG: SHR-1819 Injection
DRUG: SHR-1819 Injection Placebo

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd